WO2000069445A8 - Combination therapy for treating hypercholesterolemia - Google Patents

Combination therapy for treating hypercholesterolemia

Info

Publication number
WO2000069445A8
WO2000069445A8 PCT/US1999/010568 US9910568W WO0069445A8 WO 2000069445 A8 WO2000069445 A8 WO 2000069445A8 US 9910568 W US9910568 W US 9910568W WO 0069445 A8 WO0069445 A8 WO 0069445A8
Authority
WO
WIPO (PCT)
Prior art keywords
amount
pharmaceutical compositions
cholesterol
hypercholesterolemia
atherosclerosis
Prior art date
Application number
PCT/US1999/010568
Other languages
French (fr)
Other versions
WO2000069445A1 (en
Inventor
Chad Cori Huval
Stephen Randall Holmes-Farley
John S Petersen
Pradeep K Dhal
Original Assignee
Geltex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geltex Pharma Inc filed Critical Geltex Pharma Inc
Priority to AU39880/99A priority Critical patent/AU3988099A/en
Priority to PCT/US1999/010568 priority patent/WO2000069445A1/en
Publication of WO2000069445A1 publication Critical patent/WO2000069445A1/en
Publication of WO2000069445A8 publication Critical patent/WO2000069445A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount. The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.
PCT/US1999/010568 1999-05-13 1999-05-13 Combination therapy for treating hypercholesterolemia WO2000069445A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU39880/99A AU3988099A (en) 1999-05-13 1999-05-13 Combination therapy for treating hypercholesterolemia
PCT/US1999/010568 WO2000069445A1 (en) 1999-05-13 1999-05-13 Combination therapy for treating hypercholesterolemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/010568 WO2000069445A1 (en) 1999-05-13 1999-05-13 Combination therapy for treating hypercholesterolemia

Publications (2)

Publication Number Publication Date
WO2000069445A1 WO2000069445A1 (en) 2000-11-23
WO2000069445A8 true WO2000069445A8 (en) 2001-07-26

Family

ID=22272752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010568 WO2000069445A1 (en) 1999-05-13 1999-05-13 Combination therapy for treating hypercholesterolemia

Country Status (2)

Country Link
AU (1) AU3988099A (en)
WO (1) WO2000069445A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373438A (en) * 2001-02-10 2002-09-25 Reckitt & Colmann Prod Ltd Cholesterol lowering compositions
BR0308515A (en) * 2002-03-18 2005-02-01 Pharmacia Corp Combination of an aldosterone receptor antagonist with nicotinic acid or a nicotinic acid derivative
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CN103012789B (en) * 2011-09-23 2015-02-25 北大方正集团有限公司 Preparation method of niacin sevelamer
WO2021150958A1 (en) * 2020-01-24 2021-07-29 Schelling D Christopher Treatment methods using a combination of pantethine and a vanin agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6203785B1 (en) * 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
GB2329334A (en) * 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents

Also Published As

Publication number Publication date
WO2000069445A1 (en) 2000-11-23
AU3988099A (en) 2000-12-05

Similar Documents

Publication Publication Date Title
CA2289717A1 (en) Novel therapy for constipation
WO1997049736A3 (en) Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
WO2000032656A3 (en) Polymers containing spirobicyclic ammonium moieties and use thereof
CA2309027A1 (en) Method for treating hypercholesterolemia with unsubstituted polydiallylamine
WO2002026262A3 (en) Compositions for reducing side effects in chemotherapeutic treatments
CA2253593A1 (en) Prevention and treatment of colorectal cancer by 6-fluoroursodeoxycholic acid (6-fudca)
AU7601998A (en) Composition and methods for transdermal delivery of acid labile drugs
WO1998040375A3 (en) COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
WO2000054759A3 (en) Lxr modulators
WO2001015674A3 (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
AU1585601A (en) Transdermal administration of huperzine
AU752280C (en) Conjugate of therapeutic agent for joint disease and hyaluronic acid.
WO2001049275A3 (en) Methods and compositions for mitigating pain using nitrate esters
WO2002102743A3 (en) DEUTERATED N-SUBSTITUTED AND α-SUBSTITUTED DIPHENYLALKOXY ACETIC ACID AMINO ALKYL ESTERS AND MEDICAMENTS CONTAINING THESE COMPOUNDS
CA2280773A1 (en) Methods for the administration of amifostine
NZ514558A (en) Viral treatment
WO2000072835A3 (en) Topical application of muscarinic and opioid agents for treatment of tinnitus
WO2000069445A8 (en) Combination therapy for treating hypercholesterolemia
WO2001085139A3 (en) Semi-solid delivery vehicle and pharmaceutical compositions
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
WO2002072104A3 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
AU1656997A (en) Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds
WO2000064428A3 (en) Polyether-based bile acid sequestrants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase